Loading
Pulse Biosciences, Inc. Stock: price and insider trades · United States
1 insider bought €86k of shares over the last 90 days, the latest filed 28 Aug 2026.
Pulse Biosciences, Inc.: what insiders have been doing
Every trade that managers of Pulse Biosciences, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. 3 insiders have disclosed 6 filings since 18 October 2025.
Only purchases show up on the open market, 3 purchases in all worth €11.1M, filed by 2 insiders. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The largest single trade was a purchase of €11.0M by Duggan Robert W, published on 15 May 2026, equal to 0.39% of the market capitalisation. The buyers include 2 senior executives.
The clock since the last published purchase (28 August 2026) now reads 51 days. The median gap between a trade and its publication by SEC (Form 4) is 4 days. US insiders must file a Form 4 within two business days of a trade.
With 6 filings in twelve months, the company is quieter than the median of 19 filings across the 5,810 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at 23 purchases and 2 sales. The 10-K for the year ended 31 December 2025 shows 350,000 USD of revenue and -72.8 m USD of net income.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
58
Thresholds
n/a
Buy Volume
€121M
23 ops. · all time
Sell Volume
€1M
2 ops. · all time
Who traded when
BuySaleRobert W. Duggan5 buys
Liane Rae Teplitsky2 buys
Burke Thomas Barrett1 sale
Darrin Uecker1 sale
Since the insiders bought
- -11.3%Entry US$50.33 · Close 15 Oct 2026 US$44.63
- +74.3%Entry US$25.61 · Close 15 Oct 2026 US$44.63
- +41.3%Entry US$11.95 · Close at T+365 US$16.89
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Pulse Biosciences, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$62.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,064 of 24,148 companies
15.1
score / 100
Value28
Quality2
FCF yld-1.6%
Earn yld-2.2%
EV/EBITDA·
ROE-78%
Gross mgn-54%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$46.32
Analyst consensus
6 analystsStrong buy
US$55.00Target US$62.33(+35%)US$73.00
Income statement
RevenueUS$350k
Gross profit-US$189k-54% margin
EBITDA-US$75.9M-21677% margin
Net income-US$72.8M-20794.6% margin
Valuation
PER (forward)-39.6x
P/Book33.0x
Beta1.57
Balance sheet & cash
Market capUS$3.3B
Total debtUS$7.5M
Free Cash Flow-US$54.5M
Debt / Equity7%
Profitability & ownership
ROE-78.5%
ROA-44.3%
% insiders71.0%
% institutions15.4%
Last declaration on 28 August 2026
Declarations58 total
1,036 shares@ US$48.2350.0013% mcap50.0% of flowCommon StockSEC:0001437749-26-029233:0
Canonical exit: 24 Nov 2026 (T+90)
1,034 shares@ US$48.350.0013% mcap50.0% of flowCommon StockSEC:0001437749-26-029233:1
Canonical exit: 26 Nov 2026 (T+90)
660,233 shares@ US$19.690.39% mcap5.9% of flowCommon StockSEC:0001437749-26-017478:0
Canonical exit: 9 Aug 2026 (T+90)
5,000 shares@ US$1.534.8% of flowCommon StockSEC:0001437749-26-005144:0
20,000 shares@ US$1.530.0009% mcap19.2% of flowCommon StockSEC:0001437749-26-004438:0
20,000 shares@ US$1.530.0009% mcap19.3% of flowCommon StockSEC:0001437749-26-003840:0
4,600 shares@ US$1.530.0002% mcap4.5% of flowCommon StockSEC:0001437749-25-030665:0
20,000 shares@ US$1.5319.4% of flowCommon StockSEC:0001437749-25-029646:0
25,000 shares@ US$4.0021.3% of flowCommon StockSEC:0001437749-25-029432:0
25,000 shares@ US$4.0021.5% of flowCommon StockSEC:0001437749-25-029104:0
34,659 shares@ US$14.660.2% of flowCommon StockSEC:0001437749-25-028988:0
Canonical exit: 9 Dec 2025 (T+90)
15,000 shares@ US$16.400.0076% mcap53.6% of flowCommon StockSEC:0001437749-25-020563:0
30,121 shares@ US$11.0060.8% of flowCommon StockSEC:0001437749-25-003449:0
50,000 shares@ US$17.4290.7% of flowCommon StockSEC:0001437749-24-038145:0
5,187,824 shares@ US$11.0029.2% of flowCommon StockSEC:0000950170-24-138177:0
45,404 shares@ US$17.130.4% of flowCommon StockSEC:0000950170-24-136901:0
Canonical exit: 12 Mar 2025 (T+90)
55,256 shares@ US$17.180.5% of flowCommon StockSEC:0001437749-24-037766:0
Canonical exit: 13 Mar 2025 (T+90)
6,054 shares@ US$16.740.1% of flowCommon StockSEC:0001437749-24-037509:0
Canonical exit: 11 Mar 2025 (T+90)
3,000 shares@ US$11.0040.2% of flowCommon StockSEC:0001437749-24-030292:0
543 shares@ US$11.000.6% of flowCommon StockSEC:0001437749-24-023232:0
650 sharesCommon StockSEC:0001437749-24-022356:0
60,242 sharesCommon StockSEC:0001437749-24-022360:0
5,187,824 sharesCommon StockSEC:0001437749-24-022358:0
3,000 sharesCommon StockSEC:0001437749-24-022341:0
1,086 sharesCommon StockSEC:0001437749-24-022339:0
25 of 58 declarations
About Pulse Biosciences, Inc.
Pulse Biosciences, Inc. is a United States-based medical technology and bioelectric medicine company listed on the Nasdaq market under the ticker PLSE. The company focuses on non-thermal ablation technologies and is built around its proprietary nPulse™ platform, which uses Nanosecond Pulsed Field Ablation (nsPFA™) energy to deliver extremely short electrical pulses intended to target cells while sparing adjacent non-cellular tissue. In investor materials and company filings, Pulse Biosciences positions itself as a developer of novel therapeutic solutions for areas where current treatment options remain incomplete or suboptimal. ([investors.pulsebiosciences.com](https://investors.pulsebiosciences.com/?utm_source=openai))
Founded in 2014, the company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. That corporate transition reflects a broader strategic evolution from an early-stage technology developer into a clinical-stage medtech platform company. Over time, the business has sharpened its focus on higher-value healthcare applications, particularly atrial fibrillation, while still maintaining optionality in other soft-tissue ablation use cases. ([stockanalysis.com](https://stockanalysis.com/stocks/plse/company/?utm_source=openai))
Read moreShow less
Pulse Biosciences’ product portfolio is centered on several nPulse-branded systems. The CellFX System is described by the company as its first commercial product based on Nano-Pulse Stimulation (NPS™) technology. Beyond that, the company is advancing the nPulse Vybrance Percutaneous Electrode System, the nPulse Cardiac Surgical Clamp, the nPulse Cardiac Catheter System, and the nPulse Console platform. Together, these programs suggest a strategy of expanding from dermatologic or soft-tissue applications into cardiac electrophysiology, where the clinical and commercial opportunity is materially larger but also more demanding from a regulatory and execution standpoint. ([investors.pulsebiosciences.com](https://investors.pulsebiosciences.com/?utm_source=openai))
From a competitive perspective, Pulse Biosciences occupies a niche position in a field dominated by larger medical device companies and established electrophysiology players. Its key differentiators are its patented nsPFA mechanism, its non-thermal approach, and its broad intellectual property portfolio. The company argues that these attributes may improve safety, preserve surrounding tissue, and potentially support better procedural outcomes compared with conventional thermal ablation methods. For investors, this makes PLSE a high-risk, high-upside development story rather than a mature commercial franchise. ([pulsebiosciences.com](https://www.pulsebiosciences.com/about-us/?utm_source=openai))
Recent developments have reinforced the company’s clinical momentum. In 2025 and early 2026, Pulse Biosciences issued multiple quarterly and annual business updates, presented early clinical data on its nPulse Cardiac Catheter program, and announced a research collaboration with The University of Texas MD Anderson Cancer Center to evaluate nsPFA for benign and malignant thyroid tumors. Those updates indicate a company that is still in the evidence-building phase, with future value likely to depend on clinical readouts, regulatory progress, and eventual physician adoption. The company remains headquartered in the United States and continues to communicate as a Nasdaq-listed medtech innovator with ambitions to scale its platform across multiple therapeutic areas. ([investors.pulsebiosciences.com](https://investors.pulsebiosciences.com/news-releases/news-release-details/pulse-biosciences-reports-business-updates-and-fourth-quarter-1?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
